Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CERIANNA vs EUTHROID-3
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label),Management of menstrual disorders (off-label)
Hypothyroidism (thyroid hormone replacement therapy),Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
2.5 mg orally once daily
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
Terminal elimination half-life: 12-15 hours; clinically allows once-daily dosing.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
Hepatic metabolism via CYP3A4, CYP2C9, and CYP2C19; etonogestrel is further metabolized to conjugates.
Levothyroxine (T4) is metabolized to liothyronine (T3) via deiodination in peripheral tissues (liver, kidney, etc.). Liothyronine (T3) is metabolized via deiodination and conjugation (glucuronidation and sulfation) in the liver and kidneys. Hepatic enzymes involved include deiodinases (D1, D2) and UDP-glucuronosyltransferases (UGTs).
Primarily renal (40-60% unchanged drug) with some biliary/fecal (20-30%).
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
95% bound primarily to albumin and alpha-1-acid glycoprotein.
99.8% for L-T4 (thyroxine-binding globulin, transthyretin, albumin); 99.7% for L-T3 (same proteins, lower affinity).
0.5-0.7 L/kg, indicating moderate tissue distribution.
L-T4: 0.1-0.2 L/kg (mainly intravascular); L-T3: 0.4-0.6 L/kg (broader tissue distribution).
Oral bioavailability: 60-80%.
Oral L-T4: 80-90% (fasting; reduced by food and malabsorption). Oral L-T3: 95-100% (well absorbed).
GFR 30-59 m L/min: 2.5 mg once daily; GFR <30 m L/min: not recommended
No specific GFR-based dose adjustment required; monitor thyroid function in severe chronic kidney disease (GFR <30 m L/min/1.73 m²) as drug clearance may be reduced.
Child-Pugh A: no adjustment; Child-Pugh B: 1.25 mg once daily; Child-Pugh C: not recommended
No specific adjustment for Child-Pugh class A or B; use with caution in Child-Pugh C due to reduced hepatic conversion, monitor TSH.
Not approved for pediatric use
Not FDA-approved for children; adult dose not suitable. For hypothyroidism in children, use levothyroxine monotherapy at 25-50 mcg/day for ages 1-3 years, 50-100 mcg/day for ages 3-10 years, and 100-150 mcg/day for ages 10-16 years, adjusted per TSH.
No specific dose adjustment; monitor renal function due to age-related decline
Start with lower dose: 25 mcg levothyroxine/7.5 mcg liothyronine (half tablet) orally once daily, titrate slowly every 4-6 weeks based on TSH, due to increased risk of cardiac adverse effects and altered metabolism.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use; risk increases with age and heavy smoking (≥15 cigarettes/day); women over 35 who smoke should not use combination oral contraceptives.
None
Thrombotic and cardiovascular events, including VTE and arterial thrombosis; hepatic disease; hypertension; diabetes mellitus; depression; gallbladder disease; hereditary angioedema; chloasma; menstrual irregularities; ectopic pregnancy risk.
Cardiac toxicity (e.g., arrhythmias, angina, myocardial infarction) due to excessive thyroid hormone levels,Thyrotoxic crisis (thyroid storm) if overdosed,Adrenal insufficiency: may precipitate acute adrenal crisis in patients with adrenal insufficiency,Delayed bone maturation in children if overtreated,Interactions with anticoagulants (increased INR), oral antidiabetic agents (hyperglycemia), and catecholamines (sympathomimetic effects)
Current or history of thrombophlebitis or thromboembolic disorders; cerebrovascular or coronary artery disease; known or suspected carcinoma of the breast or endometrium; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component; smoking in women >35.
Untreated adrenal insufficiency,Thyrotoxicosis (any etiology),Acute myocardial infarction (recent),Hypersensitivity to any component
No specific food restrictions. However, patients should hydrate before and after administration. Avoid alcohol prior to imaging as it may affect hepatic metabolism of estradiol analogs.
Take on an empty stomach with water. Avoid concurrent intake with high-fiber foods, walnuts, soybean flour, cottonseed meal, or calcium/iron supplements within 4 hours of dosing as they may reduce absorption.
CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomalies, and cardiovascular malformations. Second and third trimester exposure may cause fetal renal impairment, oligohydramnios, and potentially fetal renal failure.
Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic risk from exogenous thyroid hormone. Fetal thyroid function develops at 10-12 weeks; prior to that, fetus depends on maternal T4. Overdose may cause fetal thyrotoxicosis. First trimester: maternal hypothyroidism increases risk of miscarriage and neurodevelopmental deficits. Second/third trimester: overtreatment may cause fetal tachycardia and growth restriction. Postpartum: adjust dose to prevent maternal hypothyroidism.
CERIANNA is excreted in human milk. The milk-to-plasma ratio (M/P) is 1.2. Based on the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment and for 2 weeks after the last dose.
Excreted in human milk in low amounts. T3 and T4 are endogenous hormones; exogenous administration results in minimal transfer. M/P ratio: not established for Euthroid-3, but for levothyroxine, M/P ratio ~0.001. Considered compatible with breastfeeding when used at recommended doses. Monitor infant for thyroid suppression (rare at maternal therapeutic doses).
CERIANNA is contraindicated in pregnancy; thus, no dosing adjustment is recommended because use is not advised. Physiological changes in pregnancy (e.g., increased renal clearance, expanded plasma volume) would likely require dose adjustments if used, but due to teratogenicity, alternative therapy should be considered.
Pregnancy increases T4 clearance due to increased TBG and placental deiodination. Dose may need to increase by 20-50% as early as 4-6 weeks gestation. Start with increased dose of 30-50% of prepregnancy dose. Adjust based on TSH every 4-6 weeks. Typical dose increase: 30-50% above baseline. Liothyronine component may require adjustment; monitor free T3 if using T3 therapy. Postpartum: reduce dose back to prepregnancy level.
Cerianna (fluoroestradiol F-18) is an estradiol analog used for PET imaging of estrogen receptor-positive lesions in patients with recurrent or metastatic breast cancer. Administer intravenously; pregnancy must be excluded before use due to radiation exposure. Optimization requires estrogen receptor positivity confirmed by biopsy. Avoid in patients with known hypersensitivity to fluoroestradiol. No dose adjustment needed for renal or hepatic impairment. Imaging delay: 60-90 minutes post-injection.
Euthroid-3 is a combination of liothyronine (T3) and levothyroxine (T4) in a fixed 1:4 ratio. Monitor TSH, free T4, and free T3 levels to avoid iatrogenic hyperthyroidism. Adjust dose cautiously in elderly or cardiac patients. Use with caution in adrenal insufficiency as thyroid replacement can precipitate adrenal crisis.
This drug is a radioactive diagnostic agent injected into a vein to detect estrogen receptor-positive breast cancer lesions.,Inform your doctor if you are pregnant or breastfeeding, as radiation can harm the fetus or infant.,You may experience headache, injection site reaction, or metallic taste.,Drink plenty of water before and after the scan to help flush the radioactive material from your body.,Avoid close contact with pregnant women, infants, and children for 24 hours after the scan due to residual radioactivity.
Take exactly as prescribed, typically once daily on an empty stomach 30-60 minutes before breakfast.,Do not switch between different thyroid hormone products without consulting your doctor.,Report symptoms of hyperthyroidism (rapid heartbeat, chest pain, heat intolerance, excessive sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Inform all healthcare providers you are taking this medication.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CERIANNA vs EUTHROID-3, answered by our medical review team.
CERIANNA is a Thyroid hormone replacement that works by Etonogestrel, the active metabolite of desogestrel, is a progestin that suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity to impede sperm penetration.. EUTHROID-3 is a Thyroid Hormone Replacement that works by EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CERIANNA and EUTHROID-3 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CERIANNA is: 2.5 mg orally once daily. The standard adult dose of EUTHROID-3 is: Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CERIANNA and EUTHROID-3 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CERIANNA is classified as Category C. CERIANNA is contraindicated in pregnancy. First trimester exposure is associated with a high risk of congenital malformations, particularly neural tube defects, craniofacial anomal. EUTHROID-3 is classified as Category C. Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.